导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.49% | 3257/4773 |
| 近一周 | -1.88% | 823/5462 |
| 近一月 | -2.03% | 1135/5421 |
| 近一季 | -1.93% | 1101/5209 |
| 近半年 | -2.41% | 1890/4920 |
| 近一年 | -1.90% | 2940/4366 |
| 近两年 | 31.28% | 2224/2954 |
| 近三年 | 19.50% | 1484/2253 |
| 成立以来 | 57.52% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.16% 4051/4961 |
5.75% 2872/5312 |
- - |
- - |
| 2025 | 14.92% 2581/4813 |
-0.49% 2270/3635 |
2.68% 1431/4076 |
10.45% 3289/4524 |
1.83% 1199/4813 |
| 2024 | 16.60% 790/3463 |
3.42% 575/2808 |
-0.18% 698/3014 |
15.33% 1748/3129 |
-2.07% 1944/3463 |
| 2023 | -7.95% 967/2656 |
1.26% 1607/2280 |
-4.65% 1240/2385 |
1.81% 274/2515 |
-6.37% 1738/2655 |
| 2022 | -16.40% 477/2207 |
-10.76% 419/1919 |
2.37% 1306/2016 |
-11.92% 611/2113 |
3.90% 620/2208 |
| 2021 | 1.04% 695/1822 |
-2.01% 571/1255 |
3.70% 958/1330 |
-3.31% 630/1466 |
2.83% 510/1822 |
| 2020 | 17.76% 758/1250 |
-7.93% 581/1028 |
13.74% 597/1067 |
7.06% 804/1164 |
5.03% 813/1184 |
| 2019 | 23.54% 626/1092 |
23.92% 537/754 |
-5.24% 460/804 |
-0.16% 581/850 |
5.38% 724/918 |
| 2018 | -24.84% 334/834 |
- - |
- - |
- - |
-11.87% 373/691 |
| 2017 | 15.35% 247/714 |
- - |
- - |
- - |
- - |
| 2016 | -9.99% 273/605 |
- - |
- - |
- - |
- - |
| 2015 | 19.07% 121/575 |
- - |
- - |
- - |
- - |
| 2014 | 40.76% 124/237 |
- - |
- - |
- - |
- - |
| 2013 | -10.08% 152/186 |
- - |
- - |
- - |
- - |
| 2012 | 14.30% 16/140 |
- - |
- - |
- - |
- - |
| 2011 | -19.31% 29/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华安上证50ETF联接A VS. 长安沪深300非周期A(740101) |